BBT003 / Bambusa Therapeutics - LARVOL DELTA

BBT003, A NOVEL IL-23P19 X TL1A BISPECIFIC ANTIBODY WITH EXTENDED HALF-LIFE, DEMONSTRATES A POTENTIAL BEST-IN-DISEASE PROFILE IN PRECLINICAL MODELS OF INFLAMMATORY BOWEL DISEASE (UEGW 2026) - "This TL1A receptor-selective profile was not observed with tulisokibart or afimkibart analogues and was more pronounced than that of a duvakitug analogue...In the TNBS-induced mouse colitis model, BBT003 outperformed single-targeting mAbs including guselkumab and tulisokibart analogues, and demonstrated dose-dependent, statistically significant efficacy in reducing disease activity index, colon histopathology, inflammation and fibrosis while restoring body weights... Dual blockade of the IL-23 and TL1A pathways by BBT003 demonstrates the potential to achieve better efficacy over single-targeting mAbs in IBD, with enhanced inhibition of in vitro biological functions and superior in vivo anti-inflammatory/anti-fibrotic and disease-modifying effects in preclinical models. Tolerability at the highest tested dose in cynomolgus monkeys suggests potentially a wide therapeutic window in humans. Its half-life extension technology further supports the potential for more convenient..."

Bispecific • Preclinical • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IFNG • IL17A • IL23A • TNFA • TNFRSF25

Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs (PRNewswire) - "Key uses of proceeds: Advance BBT003 and BBT004 through IND-enabling studies and into early clinical development, maintaining Bambusa's pace of advancement. Broaden Bambusa's bispecific antibody platform into new I&I indications and deepen the pipeline. Strengthen core development infrastructure to support rapid progression through upcoming clinical and regulatory milestones."

Financing • Immunology • Rheumatology

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases (PRNewswire) - "Bambusa Therapeutics, Inc...today announced the successful completion of its oversubscribed Series A financing of approximately $90 million. The round was led by new investor RA Capital Management, with participation from new investors including Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management. All existing investors also participated. The funding will support the advancement of Bambusa's lead programs through Phase I trials and drive further pipeline development...Two of Bambusa's four programs are on track to enter the clinic in Q1 2025 and mid-2025, respectively. BBT001...intended to supplant the current standard of care for a range of dermatological conditions. BBT002...created as a 'platform in a molecule' with applications across respiratory, dermatology, and gastroenterology indications...BBT003 and BB004, also have best-in-disease potential in the inflammatory bowel diseases and rheumatological indications."

Financing • New P1 trial • Dermatology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Rheumatology